LEGN · Legend Biotech Corporation

Legend Biotech Corporation reported preliminary net trade sales of approximately $597 million for its lead product, CARVYKTI, for the quarter ended March 31, 2026. This figure was disclosed pursuant to the existing Collaboration and License Agreement with Janssen Biotech, Inc. and Janssen Pharmaceutica NV. The sales data relies entirely on information provided by Janssen, and Legend Biotech explicitly stated it has not independently verified the accuracy of the figure. Consequently, investors should note that the final revenue and gross profit amounts recorded in Legend Biotech’s consolidated statement of operations remain subject to management's completion of financial statements for the period. The company further noted that its independent registered public accountants have not audited, reviewed, or performed any procedures on this data, and thus have not provided assurance regarding these preliminary results. This disclosure provides an early indication of commercial performance for the cell therapy product, though final recognized revenue may differ based on accounting adjustments and the terms of the Janssen collaboration agreement.